Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00103155|
Recruitment Status : Unknown
Verified August 2005 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : February 8, 2005
Last Update Posted : September 20, 2013
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Ultrasound-guided radiofrequency ablation may be effective treatment for thyroid cancer.
PURPOSE: This phase I trial is studying the side effects of radiofrequency ablation in treating patients who are undergoing surgery for thyroid cancer.
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer||Procedure: conventional surgery Procedure: radiofrequency ablation||Phase 1|
- Determine the frequency of complications associated with radiofrequency ablation (RFA) in patients with low-risk papillary thyroid cancer undergoing thyroidectomy.
- Determine the utility of RFA as a treatment option for these patients.
OUTLINE: This is a pilot study.
An electrosurgical probe is placed by ultrasound guidance into the center of the thyroid tumor. Patients undergo radiofrequency ablation directly to the tumor until the target temperature is reached* for 5 minutes. Patients then undergo standard thyroidectomy.
NOTE: *Takes approximately 15-30 minutes to reach target temperature.
After completion of study treatment, patients are followed at day 1, between days 14-21, and then periodically as deemed necessary.
PROJECTED ACCRUAL: A total of 15-40 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study|
|Study Start Date :||September 2004|
- Frequency of radiofrequency ablation-associated complications at 2 weeks
- Amount of tumor destruction at 2 weeks
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00103155
|United States, California|
|UCSF Comprehensive Cancer Center|
|San Francisco, California, United States, 94143-1674|
|Study Chair:||Electron Kebebew, MD||University of California, San Francisco|